Tokyo, Sept 28, 2007 (JCN Newswire) - Kissei Pharmaceutical Co., Ltd. (TSE: 4547) and Eisai Co., Ltd. (TSE: 4523) announced the conclusion of a license agreement for Glufast(R) (tablets, generic name: mitiglinide calcium hydrate), a rapid-acting insulin secretagogue originally created by Kissei. In this agreement, Eisai gained the exclusive development and commercialization rights of Glufast(R) in China from Kissei.
